摘要
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death worldwide, driven by lifelong accumulation of cholesterol carried by apolipoprotein B (apoB)-containing lipoproteins into the arterial wall. In the normotriglyceridaemic state, low-density lipoprotein particles (LDL-P) constitute approximately 90% of circulating apoB-containing particles; consequently, reducing LDL-P number and their cholesterol content (LDL-C) has been the cornerstone of lipid-lowering therapies. Despite substantial reductions in LDL-C achieved with statins and newer agents, cardiovascular events persist, frequently in individuals whose LDL-C levels meet or fall below guideline-recommended targets.1 Contributors to this ‘residual’ cardiovascular risk are triglyceride-rich lipoproteins (TRLs) and their remnants, which in large observational studies and Mendelian randomization analyses appear causally linked to ASCVD risk.2 TRLs constitute 5–10% of total apoB-containing particles when triglyceride concentrations are <1.7 mmol/L; however, their remnants can carry 10–40 times more cholesterol per particle than an LDL-P.3 These remnants are larger than LDL yet small enough to penetrate the endothelium and accelerate foam-cell formation. Furthermore, free fatty acids released from TRL lipolysis promote pro-inflammatory conditions, potentially contributing to plaque destabilization.2 Notwithstanding this compelling biological rationale, prior trials of triglyceride-targeted therapies have achieved only modest reductions in triglycerides and TRLs and have not consistently reduced cardiovascular risk in primary analyses.4 Insights from the PROMINENT trial suggest that fibrates, which reduce triglycerides and remnant cholesterol without reducing apoB in patients with baseline triglycerides of 3.1 mmol/L, do not reduce ASCVD risk, underscoring the need for more potent therapeutic approaches targeting alternative biological pathways.5 Angiopoietin-like protein 3 (ANGPTL3) is a regulator of TRL metabolism that inhibits lipoprotein and endothelial lipases, thereby modulating not only triglyceride levels but also the production of LDL-P from very-low-density lipoprotein particles (VLDL-P), the clearance of remnants by the hepatic LDL receptor-related protein 1, and LDL-C levels independent of the LDL receptor.2 Loss-of-function variants in the ANGPTL3 gene are associated with lower triglycerides, LDL-C, high-density lipoprotein cholesterol (HDL-C), and apoB, and reduced risk of ASCVD.6 Thus, inhibiting ANGPTL3 may reduce TRL-associated cardiovascular risk (Figure 1; A). Mechanism and clinical implications of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3. (A) ANGPTL3 biology and solbinsiran mechanism of action. (B) Key findings from the PROLONG-ANG3 Phase II trial and potential clinical impact. ApoB = apolipoprotein B; ANGPTL3 = angiopoietin-like 3; CV = cardiovascular; CRP = C-reactive protein; EL = endothelial lipase; GalNAc = N-acetylgalactosamine; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; LPL = lipoprotein lipase; mRNA = messenger RNA; siRNA = Small interfering RNA; TRL = triglyceride-rich lipoprotein. Solbinsiran (LY3561774) is an N-acetylgalactosamine (GalNAc)-conjugated small interfering RNA (siRNA) that targets hepatic ANGPTL3 mRNA degradation. The GalNAc conjugation exploits the asialoglycoprotein receptor for efficient and highly selective hepatocyte uptake, reducing extrahepatic exposure and minimizing off-target effects.7 This strategy confers significant safety advantages over earlier ANGPTL3-targeting therapies, including vupanorsen, an antisense oligonucleotide whose development was discontinued due to dose-dependent hepatotoxicity,8 and differs mechanistically from evinacumab, a monoclonal antibody requiring monthly intravenous infusions.9 In phase 1, solbinsiran was well tolerated and produced dose-dependent reductions in ANGPTL3, triglycerides, non-HDL-C, LDL-C, and apoB. Nuclear magnetic resonance analyses demonstrated reductions in TRL and LDL-P across all size fractions, consistent with the biological effects of ANGPTL3 inhibition.7 In early 2025, results of the PROLONG-ANG3 trial, a phase 2 study of solbinsiran, were published.10 The trial tested whether quarterly subcutaneous doses of solbinsiran (100 mg, 400 mg or 800 mg) could reduce apoB-containing lipoproteins in adults with mixed dyslipidaemia already receiving moderate or high intensity statin therapy, stratified by baseline triglyceride levels. Changes in ANGPTL3, triglycerides, non-HDL-C, LDL-C, and HDL-C were assessed as secondary outcomes, with VLDL-C and hepatic fat fraction as exploratory. The trial yielded several important findings with both therapeutic promise and interpretive complexity. First, the 400 mg dose met the primary endpoint of apoB reduction, but the 800 mg dose did not, creating a counterintuitive dose-response relationship potentially explained by an unexpectedly large and random decline in apoB within the placebo group. Such spontaneous placebo group declines are uncommon in lipid-lowering trials, raising questions about population selection and trial design and underscoring the need to clarify whether apoB reductions are truly dose-dependent in larger cohorts. Second, solbinsiran achieved what fibrates could not: Simultaneous reduction of both triglyceride-rich remnants and LDL particles. This dual effect distinguishes ANGPTL3 inhibition from prior triglyceride-targeted therapies and provides a stronger biological rationale for potentially addressing residual risk more comprehensively. Third, the magnitude of triglyceride reduction (∼50%) exceeded that achieved in previous remnant-targeted trials, potentially offering sufficient potency to rigorously test the causal link between remnant cholesterol reduction and decreased incidence of ASCVD in larger outcomes studies. The substantial reduction in hepatic fat without weight loss suggests direct hepatic metabolic effects, which may extend solbinsiran’s utility beyond cardiovascular risk to the management of metabolic dysfunction-associated steatotic liver disease, though this requires validation in dedicated studies. Additionally, the decrease in HDL-C, consistent with ANGPTL3 biology, raises questions about its net impact on the overall atherogenic profile, though reductions in apoB-containing lipoproteins may outweigh this (Figure 1; B). The safety profile appeared reassuring over 6 months, notably avoiding the hepatotoxicity that terminated development of earlier ANGPTL3-targeting approaches and aligning with the favourable profile of GalNAc-siRNA conjugates.10 The quarterly dosing schedule offers practical advantages over monthly infusions, yet whether this convenience translates to improved real-world adherence remains unknown. Moreover, the inconsistent dose-response effect and relatively short follow-up limit insights into long-term safety and efficacy. Despite robust epidemiological and Mendelian randomization evidence causally linking TRLs and their remnants to ASCVD, the complexity of triglyceride metabolism and the variable effects of prior therapeutic approaches on individual lipid fractions have historically impeded the successful development of agents targeting remnant particles.2 Solbinsiran achieved substantial and sustained reductions in both TRL and LDL particle numbers with a favourable safety profile. Subcutaneous administration of solbinsiran 400 mg every 90 days achieves durable suppression of ANGPTL3 in adults with mixed dyslipidaemia, resulting in clinically meaningful reductions in all apoB-containing lipoproteins, a favourable hepatic safety profile with potential benefits on hepatic steatosis, and a convenient quarterly dosing regimen that may improve adherence relative to monthly intravenous alternatives.7,10 Whether these effects translate into reduced ASCVD events requires dedicated cardiovascular outcome trials, but these findings position solbinsiran as a promising agent for mitigating residual cardiovascular risk in patients with mixed dyslipidaemia on conventional lipid-lowering therapy. No new data were generated or analysed in support of this research. Kausik K. Ray: Professor Kausik K Ray is a leading preventative cardiologist, Professor of Public Health, Honorary Consultant Cardiologist, Head of Commercial Trials, and Deputy Director of the Imperial Clinical Trials Unit at Imperial College London. He is the Immediate Past President of the European Atherosclerosis Society and Fellow of the Academy of Medical Sciences (FMedSci). Professor Ray has established himself as the principal investigator for several major global cardiovascular prevention trials. His research portfolio encompasses over 400 publications in premier peer-reviewed journals, including New England Journal of Medicine, Lancet, and JAMA, with over 200 000 citations. For eight consecutive years, he has been recognized as one of the world's most cited researchers by Web of Science. Professor Ray's research focuses on coronary disease prevention, particularly lipid metabolism, diabetes, biomarkers, and cardiovascular risk prediction. His contributions have influenced European and American prevention guidelines and regulatory decisions by the FDA and EMA. He led the global development of Inclsiran, the first siRNA for cholesterol, European Lead for development of Bempedoic acid, the first oral lipid-lowering therapy in a decade, and the PCSK9 monoclonal programme. He leads or has led the only global registry of FH (the FH Studies Collaboration [FHSC]) and pivotal registries such as Da Vinci, Santorini, Heymans, as well as part of the academic steering group of MILOS, INTERASPIRE, and EUROASPIRE VI. Dídac Llop: Dr Dídac Llop is a researcher at the Imperial Centre for Cardiovascular Disease Prevention, led by Professor Kausik K Ray. He specializes in epidemiology, statistical analysis, data management, and atherosclerotic cardiovascular disease prevention research. His work focuses on metabolic disturbances in the general population and individuals with familial hypercholesterolaemia, investigating factors beyond LDL-C that influence cardiovascular risk. With an interdisciplinary background spanning biology, statistics, and epidemiology, Dr. Llop integrates biological insights with advanced statistical and machine learning techniques to address complex questions in cardiovascular disease prevention.